会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明申请
    • PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND
    • 制备咪唑并[1,2-b]吡啶化合物的方法
    • US20100234597A1
    • 2010-09-16
    • US12064832
    • 2006-08-22
    • Ichiro KomotoKazuaki SasakiTomohiko Gotou
    • Ichiro KomotoKazuaki SasakiTomohiko Gotou
    • C07D487/04
    • C07D487/04
    • A process for producing an imidazo[1,2-b]pyridazine compound represented by the formula (2): wherein R1, R2 and R3 are the same or different and each represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted with a halogen atom or atoms, an alkenyl group which may be substituted with a halogen atom or atoms, or an alkoxy group which may be substituted with a halogen atom or atoms, which comprises reacting a 2,3-dihydropyridazine compound represented by the formula (1): wherein R1, R2 and R3 are the same meanings as defined above, with a phosphorus oxyhalide in the presence of an organic base which is in an amount of 0.5 mole or more relative to 1 mole of the 2,3-dihydropyridazine compound and 1 mole or less relative to 1 mole of the phosphorus oxyhalide.
    • 一种制备由式(2)表示的咪唑并[1,2-b]哒嗪化合物的方法:其中R 1,R 2和R 3相同或不同,各自表示氢原子,卤素原子,可以 被卤原子或原子取代,可被卤原子或原子取代的烯基,或可以被卤原子或原子取代的烷氧基,其包括使由2,3-二氢哒嗪化合物 式(1):其中R1,R2和R3与上述定义相同,在有机碱的存在下,相对于1摩尔2,3的量,为0.5摩尔以上 - 二氢哒嗪化合物,相对于1摩尔的卤氧化磷为1摩尔以下。
    • 42. 发明授权
    • Ultrasonic treatment equipment
    • 超声波处理设备
    • US07699779B2
    • 2010-04-20
    • US10557237
    • 2004-05-18
    • Kazuaki SasakiTakashi AzumaKen-ichi KawabataShin-ichiro UmemuraTakashi OkaiTetsuya Ishikawa
    • Kazuaki SasakiTakashi AzumaKen-ichi KawabataShin-ichiro UmemuraTakashi OkaiTetsuya Ishikawa
    • A61B8/00
    • A61N7/02A61B8/06A61B8/13A61B2090/378
    • Ultrasonic treatment equipment is provided which repeats therapeutic ultrasound exposure while measuring a degree of vessel constriction on a therapeutic ultrasound exposure basis. This equipment includes: a therapeutic ultrasonic transducer 2 which exposes a blood vessel of an affected part to a focused therapeutic ultrasonic wave for a specified period of exposure time; an imaging ultrasonic probe 3 which images an ultrasound tomographic image of the affected part; a display unit 24 which displays the ultrasound tomographic image; means 21 for detecting a blood flow signal from a signal received by the imaging ultrasonic probe and determining the blood flow velocity of the blood vessels of the affected part; means 21 for calculating a rate of change in blood flow velocity during the exposure to the therapeutic ultrasonic wave or before and after the exposure to the therapeutic ultrasonic wave; and means 23 for controlling exposure conditions of the therapeutic ultrasonic wave on the basis of the rate of change in blood flow velocity, and thereby controlling the therapeutic ultrasonic transducer.
    • 提供超声波处理设备,其在治疗超声暴露基础上测量血管收缩程度时重复治疗性超声波暴露。 该设备包括:治疗超声波换能器2,其将受影响部分的血管暴露于聚焦的治疗超声波达指定的曝光时间; 成像超声波探头3,其对受影响部分的超声断层图像进行成像; 显示单元24,其显示超声断层图像; 用于从由成像超声波探头接收的信号中检测血流信号并确定受影响部分的血管的血流速度的装置21; 用于计算暴露于治疗超声波期间或暴露于治疗超声波之前和之后的血流速度变化率的装置21; 以及基于血流速度变化率来控制治疗超声波的暴露条件的装置23,由此控制治疗用超声波换能器。
    • 49. 发明授权
    • Process for producing imidazo[1,2-b]pyridazine compound
    • 咪唑并[1,2-b]哒嗪化合物的制备方法
    • US08334379B2
    • 2012-12-18
    • US12064832
    • 2006-08-22
    • Ichiro KomotoKazuaki SasakiTomohiko Gotou
    • Ichiro KomotoKazuaki SasakiTomohiko Gotou
    • C07D487/00
    • C07D487/04
    • A process for producing an imidazo[1,2-b]pyridazine compound represented by the formula (2): wherein R1, R2 and R3 are the same or different and each represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted with a halogen atom or atoms, an alkenyl group which may be substituted with a halogen atom or atoms, or an alkoxy group which may be substituted with a halogen atom or atoms, which comprises reacting a 2,3-dihydropyridazine compound represented by the formula (1): wherein R1, R2 and R3 are the same meanings as defined above, with a phosphorus oxyhalide in the presence of an organic base which is in an amount of 0.5 mole or more relative to 1 mole of the 2,3-dihydropyridazine compound and 1 mole or less relative to 1 mole of the phosphorus oxyhalide.
    • 一种制备由式(2)表示的咪唑并[1,2-b]哒嗪化合物的方法:其中R 1,R 2和R 3相同或不同,各自表示氢原子,卤素原子,可以 被卤原子或原子取代,可被卤原子或原子取代的烯基,或可以被卤原子或原子取代的烷氧基,其包括使由2,3-二氢哒嗪化合物 式(1):其中R1,R2和R3与上述定义相同,在有机碱的存在下,相对于1摩尔2,3的量,为0.5摩尔以上 - 二氢哒嗪化合物,相对于1摩尔的卤氧化磷为1摩尔以下。